Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
Study met its primary efficacy endpoint of delaying time to relapse TEL AVIV, Israel & PARIS–(BUSINESS WIRE)–Teva Pharmaceuticals Industries Ltd.…